Acadia Healthcare Company, Inc. (ACHC)

Services-Specialty Outpatient Facilities, NEC · market cap $2.6B · as of 2026-07-16

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Acadia Healthcare (ACHC) is a for-profit behavioral healthcare services operator running over 225 facilities — including 50+ inpatient psychiatric hospitals and 165 methadone clinics — across the U.S. and Puerto Rico, with ~$3.3B in 2025 revenue. The company carries $2.4B in net debt against a ~$2.9B market cap, posted a $1.1B net loss in 2025 after profitability in prior years, and faces a 24.4% short float ahead of a July 28 earnings catalyst. The pipeline facts listed (pimavanserin, ACP-204, trofinetide) appear misattributed from a pharma entity and are inconsistent with Acadia's core services business model.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Pimavanserin tartrate	Phase 2	Alzheimer's Disease Psychosis
Pimavanserin	Phase 3	Neuropsychiatric Symptoms Related to Neurodegenerative Disease
ACP-103	Phase 2	Schizophrenia
Pimavanserin 34 mg	Phase 2	Intermittent Explosive Disorder
ACP-204	Phase 3	Alzheimer's Disease Psychosis
Trofinetide	Phase 3	Rett Syndrome
pimavanserin tartrate (ACP-103)	Phase 3	Parkinson's Disease Psychosis

Price & technical context

3-month

+13.7%

6-month

+25.0%

12-month

+23.2%

52-wk range

$11.68–$35.61

vs 50-day MA

-5.6%

vs 200-day MA

+19.7%

Realized vol

65.3%

Max drawdown

-85.7%

Daily closes through 2026-09-23. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ACHC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.